{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:52:29Z","timestamp":1793321549639,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK076077, R01 DK087635, and R01 DK105821"],"award-info":[{"award-number":["R01 DK076077, R01 DK087635, and R01 DK105821"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Individuals of African ancestry carrying\n                    <jats:italic>APOL1<\/jats:italic>\n                    (apolipoprotein L1) high-risk genotypes face a markedly increased risk of kidney failure, yet tools to identify those individuals likely to progress to chronic kidney disease are lacking. Here we profiled plasma proteomes of 851 Penn Medicine BioBank participants of African ancestry (285 males and 566 females) with\n                    <jats:italic>APOL1<\/jats:italic>\n                    high-risk genotypes and preserved estimated glomerular filtration rate (eGFR) (\u226560\u2009ml\u2009min\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u20091.73\u2009m\n                    <jats:sup>\u22122<\/jats:sup>\n                    ). Using elastic net Cox regression adjusted for age, sex, eGFR and albuminuria, we derived a nine-protein APOL1 Proteomic Risk Score (APRS) that predicts a composite outcome of \u226540% eGFR decline, kidney failure or death. APRS achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%, outperforming the Kidney Failure Risk Equation (66.1%) and polygenic risk scores, with 10-year event rates of 62.5% versus 3.3% across risk quintiles. External validation in Atherosclerosis Risk in Communities and UK Biobank cohorts confirmed robust accuracy (tAUC 82\u201385%) and consistent performance across demographic and clinical subgroups. Plasma levels of APRS component proteins correlated with kidney tissue fibrosis and tubular injury pathways, indicating strong biological plausibility. By enabling early and accurate prediction of disease progression in\n                    <jats:italic>APOL1<\/jats:italic>\n                    high-risk individuals, APRS bridges the gap between genetic susceptibility and clinical translation. This scalable and biologically informed approach provides a precision medicine framework for early intervention and may accelerate development of APOL1-targeted therapies to reduce kidney disease disparities.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04337-2","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:03:00Z","timestamp":1776243780000},"page":"1701-1707","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes"],"prefix":"10.1038","volume":"32","author":[{"given":"Chenyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shola M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8875-0070","authenticated-orcid":false,"given":"Amin","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Mohandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-414X","authenticated-orcid":false,"given":"Rebecca","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiazi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-9160","authenticated-orcid":false,"given":"Joseph J.","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Surapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-0669","authenticated-orcid":false,"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-6023","authenticated-orcid":false,"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Karihaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-3907","authenticated-orcid":false,"given":"Hongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-9107","authenticated-orcid":false,"given":"Anurag","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-1720","authenticated-orcid":false,"given":"Marylyn","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-9876","authenticated-orcid":false,"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Penn Medicine BioBank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori L.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-3726","authenticated-orcid":false,"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4337_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.88","volume":"3","author":"P Romagnani","year":"2017","unstructured":"Romagnani, P. et al. Chronic kidney disease. Nat. Rev. Dis. Primers 3, 17088 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"4337_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration.","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u22122017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"4337_CR3","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage, T. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385, 1975\u20131982 (2015).","journal-title":"Lancet"},{"key":"4337_CR4","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","volume":"390","author":"A Levin","year":"2017","unstructured":"Levin, A. et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390, 1888\u20131917 (2017).","journal-title":"Lancet"},{"key":"4337_CR5","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States. NIDDK https:\/\/www.niddk.nih.gov\/health-information\/health-statistics\/kidney-disease (2024)."},{"key":"4337_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2215\/CJN.06450611","volume":"7","author":"P Muntner","year":"2012","unstructured":"Muntner, P. et al. Racial differences in the incidence of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 101\u2013107 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"4337_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"4337_CR8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183\u20132196 (2013).","journal-title":"N. Engl. J. Med."},{"key":"4337_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.semnephrol.2015.04.008","volume":"35","author":"PD Dummer","year":"2015","unstructured":"Dummer, P. D. et al. APOL1 kidney disease risk variants: an evolving landscape. Semin. Nephrol. 35, 222\u2013236 (2015).","journal-title":"Semin. Nephrol."},{"key":"4337_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ndt\/gfu391","volume":"31","author":"E Kruzel-Davila","year":"2016","unstructured":"Kruzel-Davila, E., Wasser, W. G., Aviram, S. & Skorecki, K. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol. Dial. Transplant. 31, 349\u2013358 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"4337_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129\u20132137 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4337_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.ackd.2014.06.005","volume":"21","author":"S Limou","year":"2014","unstructured":"Limou, S., Nelson, G. W., Kopp, J. B. & Winkler, C. A. APOL1 kidney risk alleles: population genetics and disease associations. Adv. Chronic Kidney Dis. 21, 426\u2013433 (2014).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"4337_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N. Engl. J. Med. 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4337_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41581-023-00721-0","volume":"19","author":"R Gbadegesin","year":"2023","unstructured":"Gbadegesin, R. & Lane, B. Inaxaplin for the treatment of APOL1-associated kidney disease. Nat. Rev. Nephrol. 19, 479\u2013480 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"4337_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2015.18202","volume":"315","author":"N Tangri","year":"2016","unstructured":"Tangri, N. et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure a meta-analysis. JAMA 315, 164\u2013174 (2016).","journal-title":"JAMA"},{"key":"4337_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1681\/ASN.0000000000000050","volume":"34","author":"ME Grams","year":"2023","unstructured":"Grams, M. E. et al. The Kidney Failure Risk Equation: evaluation of novel input variables including eGFR estimated using the CKD-EPI 2021 equation in 59 cohorts. J. Am. Soc. Nephrol. 34, 482\u2013494 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4337_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43020-9","volume":"14","author":"Y Gupta","year":"2023","unstructured":"Gupta, Y. et al. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nat. Commun. 14, 7836 (2023).","journal-title":"Nat. Commun."},{"key":"4337_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature19949","volume":"537","author":"R Aebersold","year":"2016","unstructured":"Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537, 347\u2013355 (2016).","journal-title":"Nature"},{"key":"4337_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrneph.2014.247","volume":"11","author":"H Mischak","year":"2015","unstructured":"Mischak, H., Delles, C., Vlahou, A. & Vanholder, R. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat. Rev. Nephrol. 11, 221\u2013232 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"4337_CR20","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.kint.2019.07.025","volume":"96","author":"M Kammer","year":"2019","unstructured":"Kammer, M. et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 96, 1381\u20131388 (2019).","journal-title":"Kidney Int."},{"key":"4337_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/ndt\/gfv364","volume":"31","author":"K Cisek","year":"2016","unstructured":"Cisek, K., Krochmal, M., Klein, J. & Mischak, H. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol. Dial. Transplant. 31, 2003\u20132011 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"4337_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5, e15004 (2010).","journal-title":"PLoS ONE"},{"key":"4337_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1681\/ASN.0000000000000141","volume":"34","author":"D Hirohama","year":"2023","unstructured":"Hirohama, D. et al. Unbiased human kidney tissue proteomics identifies matrix metalloproteinase 7 as a kidney disease biomarker. J. Am. Soc. Nephrol. 34, 1279\u20131291 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4337_CR24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/j.ekir.2024.04.008","volume":"9","author":"C Narjoz","year":"2024","unstructured":"Narjoz, C., Vinh-Hoang-Lan Julie, T., Rabant, M., Karras, A. & Pallet, N. Diagnostic yield of APOL1 p.N264K variant screening in daily practice. Kidney Int. Rep. 9, 1916\u20131918 (2024).","journal-title":"Kidney Int. Rep."},{"key":"4337_CR25","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1681\/ASN.2021010044","volume":"32","author":"GZ Quinn","year":"2021","unstructured":"Quinn, G. Z. et al. Renal histologic analysis provides complementary information to kidney function measurement for patients with early diabetic or hypertensive disease. J. Am. Soc. Nephrol. 32, 2863\u20132876 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4337_CR26","doi-asserted-by":"crossref","unstructured":"Hirohama, D. et al. The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health. Nat. Med. 31, 3917\u22123929 (2025).","DOI":"10.1038\/s41591-025-03872-8"},{"key":"4337_CR27","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41588-021-00909-9","volume":"53","author":"X Sheng","year":"2021","unstructured":"Sheng, X. et al. Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments. Nat. Genet. 53, 1322\u20131333 (2021).","journal-title":"Nat. Genet."},{"key":"4337_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41642-7","volume":"14","author":"RF Dubin","year":"2023","unstructured":"Dubin, R. F. et al. Proteomics of CKD progression in the chronic renal insufficiency cohort. Nat. Commun. 14, 6340 (2023).","journal-title":"Nat. Commun."},{"key":"4337_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41591-022-01869-1","volume":"28","author":"A Khan","year":"2022","unstructured":"Khan, A. et al. Genome-wide polygenic score to predict chronic kidney disease across ancestries. Nat. Med. 28, 1412\u20131420 (2022).","journal-title":"Nat. Med."},{"key":"4337_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","volume":"30","author":"L Jiang","year":"2024","unstructured":"Jiang, L. et al. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat. Med. 30, 749\u2013761 (2024).","journal-title":"Nat. Med."},{"key":"4337_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2023.13258","volume":"330","author":"H Helgason","year":"2023","unstructured":"Helgason, H. et al. Evaluation of large-scale proteomics for prediction of cardiovascular events. JAMA 330, 725\u2013735 (2023).","journal-title":"JAMA"},{"key":"4337_CR32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","volume":"25","author":"SA Williams","year":"2019","unstructured":"Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851\u20131857 (2019).","journal-title":"Nat. Med."},{"key":"4337_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","volume":"25","author":"MA Niewczas","year":"2019","unstructured":"Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25, 805\u2013813 (2019).","journal-title":"Nat. Med."},{"key":"4337_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nm.2989","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu, V. S. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat. Med. 19, 227\u2013231 (2013).","journal-title":"Nat. Med."},{"key":"4337_CR35","unstructured":"Schmidt, I. M. et al. Plasma proteomics of acute tubular injury. Nat. Commun. 15, 7368 (2024)."},{"key":"4337_CR36","first-page":"233","volume":"20","author":"Y Ren","year":"2024","unstructured":"Ren, Y., Yu, M. J., Zheng, D. N., He, W. F. & Jin, J. Lysozyme promotes renal fibrosis through the JAK\/STAT3 signal pathway in diabetic nephropathy. Arch. Med. Sci 20, 233\u2013247 (2024).","journal-title":"Arch. Med. Sci"},{"key":"4337_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm.4287","volume":"23","author":"P Beckerman","year":"2017","unstructured":"Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429\u2013438 (2017).","journal-title":"Nat. Med."},{"key":"4337_CR38","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.immuni.2021.10.004","volume":"54","author":"J Wu","year":"2021","unstructured":"Wu, J. et al. APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. Immunity 54, 2632\u20132649 (2021).","journal-title":"Immunity"},{"key":"4337_CR39","doi-asserted-by":"crossref","unstructured":"Wu, J. et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J. Clin. Invest. 131, e136329 (2021).","DOI":"10.1172\/JCI136329"},{"key":"4337_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.kint.2021.10.041","volume":"102","author":"MT McNulty","year":"2022","unstructured":"McNulty, M. T. et al. A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis. Kidney Int. 102, 136\u2013148 (2022).","journal-title":"Kidney Int."},{"key":"4337_CR41","doi-asserted-by":"crossref","unstructured":"Verma, A. et al. The Penn Medicine BioBank: towards a genomics-enabled learning healthcare system to accelerate precision medicine in a diverse population. J. Pers. Med. 12, 1974 (2022).","DOI":"10.3390\/jpm12121974"},{"key":"4337_CR42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker, L. A. et al. New creatinine- and cystatin C\u2212based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737\u20131749 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4337_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/M20-0529","volume":"173","author":"K Sumida","year":"2020","unstructured":"Sumida, K. et al. Conversion of urine protein\u2212creatinine ratio or urine dipstick protein to urine albumin\u2212creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. Ann. Intern. Med. 173, 426\u2013435 (2020).","journal-title":"Ann. Intern. Med."},{"key":"4337_CR44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4337_CR45","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712\u20131721 (2021).","journal-title":"Nat. Genet."},{"key":"4337_CR46","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41591-019-0673-2","volume":"25","author":"B Lehallier","year":"2019","unstructured":"Lehallier, B. et al. Undulating changes in human plasma proteome profiles across the lifespan. Nat. Med. 25, 1843\u20131850 (2019).","journal-title":"Nat. Med."},{"key":"4337_CR47","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/eurheartj\/ehad115","volume":"44","author":"R Deo","year":"2023","unstructured":"Deo, R. et al. Proteomic cardiovascular risk assessment in chronic kidney disease. Eur. Heart J. 44, 2095\u20132110 (2023).","journal-title":"Eur. Heart J."},{"key":"4337_CR48","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-023-05844-9","volume":"616","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. An atlas of genetic scores to predict multi-omic traits. Nature 616, 123\u2013131 (2023).","journal-title":"Nature"},{"key":"4337_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26640-w","volume":"8","author":"CH Kim","year":"2018","unstructured":"Kim, C. H. et al. Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci. Rep. 8, 8382 (2018).","journal-title":"Sci. Rep."},{"key":"4337_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"4337_CR51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","volume":"590","author":"D Taliun","year":"2021","unstructured":"Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290\u2013299 (2021).","journal-title":"Nature"},{"key":"4337_CR52","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.jacc.2021.04.035","volume":"77","author":"JD Wright","year":"2021","unstructured":"Wright, J. D. et al. The ARIC (Atherosclerosis Risk In Communities) study: JACC Focus Seminar 3\/8. J. Am. Coll. Cardiol. 77, 2939\u20132959 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4337_CR53","doi-asserted-by":"crossref","unstructured":"Rosenberg, A. et al. Surrogate endpoints in apolipoprotein L1\u2212associated kidney disease: evaluation in three cohorts. Clin. J. Am. Soc. Nephrol. 20, 23\u221230 (2025).","DOI":"10.2215\/CJN.0000000000000575"},{"key":"4337_CR54","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1109\/34.709601","volume":"20","author":"TK Ho","year":"1998","unstructured":"Ho, T. K. The random subspace method for constructing decision forests. IEEE Trans. Pattern Anal. Mach. Intell. 20, 832\u2013844 (1998).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"4337_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1467-9868.2010.00740.x","volume":"72","author":"N Meinshausen","year":"2010","unstructured":"Meinshausen, N. & B\u00fchlmann, P. Stability selection. J. R. Stat. Soc. B 72, 417\u2013473 (2010).","journal-title":"J. R. Stat. Soc. B"},{"key":"4337_CR56","doi-asserted-by":"publisher","first-page":"2747431","DOI":"10.1155\/2017\/2747431","volume":"2017","author":"QY Yin","year":"2017","unstructured":"Yin, Q. Y., Li, J. L. & Zhang, C. X. Ensembling variable selectors by stability selection for the Cox model. Comput. Intell. Neurosci. 2017, 2747431 (2017).","journal-title":"Comput. Intell. Neurosci."},{"key":"4337_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0332-6","volume":"17","author":"AN Kamarudin","year":"2017","unstructured":"Kamarudin, A. N., Cox, T. & Kolamunnage-Dona, R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med. Res. Methodol. 17, 53 (2017).","journal-title":"BMC Med. Res. Methodol."},{"key":"4337_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 26, 565\u2013574 (2006).","journal-title":"Med. Decis. Making"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04337-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:03:48Z","timestamp":1780927428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4337"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04337-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The laboratory of K.S., including C.L., G.Q., A.A., M.Z., T.V. and S.M., receives research support from Gilead, Novo Nordisk, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Regeneron, Genentech and Calico Life Sciences. J.C. is a scientific advisor receiving fees from SomaLogic and Healthy.io. S.M.R., R.P., V.B., X.Q., T.S., J.J.L., N.F., W.F.D. and L.L.J. are employees and stockholders of Novartis. A.K. is an employee of Novo Nordisk. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}